The abstract is read at the publisher; the summary is JClub's.
Engineered allogeneic trifunctional NK cells plus rituximab without lymphodepletion achieved rapid B-cell depletion and 73% and 52% proteinuria reductions in refractory mixed class IV/V lupus nephritis.
- Why it matters: Refractory mixed class IV+V lupus nephritis is highly treatment-resistant, and rituximab often incompletely depletes B cells, while CAR-T approaches typically require lymphodepleting preconditioning.
- What they did: The team engineered off-the-shelf NK cells to express NKG2D, high CD16, and membrane-bound IL-15/IL-15Rα, then tested NKG2D-MICA/B killing and enhanced ADCC in vitro and persistence in NOG mice up to 90 days.
- The result: In a first-in-human trial (NCT06676631) of two patients, the therapy was well tolerated with no cytokine release syndrome or neurotoxicity, sustained SRI-4 responses, and showed feasibility and meaningful clinical improvement on low-dose steroids.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.